Stefanos Theoharis
Chief Executive Officer bei Onechain Immunotherapeutics
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Pablo Menéndez | M | - |
Onechain Immunotherapeutics
 Onechain Immunotherapeutics Medical SpecialtiesHealth Technology Onechain Immunotherapeutics develops oncological therapeutic tools. The company is based in Barcelona, Spain. The Spanish company was founded in 2020 by Pablo Menéndez. The CEO is Jorge Alemany. | - |
| Albert Carreras | M | - |
Onechain Immunotherapeutics
Onechain Immunotherapeutics Medical SpecialtiesHealth Technology Onechain Immunotherapeutics develops oncological therapeutic tools. The company is based in Barcelona, Spain. The Spanish company was founded in 2020 by Pablo Menéndez. The CEO is Jorge Alemany. | - |
| Albert Ferrer | M | - |
Onechain Immunotherapeutics
Onechain Immunotherapeutics Medical SpecialtiesHealth Technology Onechain Immunotherapeutics develops oncological therapeutic tools. The company is based in Barcelona, Spain. The Spanish company was founded in 2020 by Pablo Menéndez. The CEO is Jorge Alemany. | - |
| Laura Rodriguez | F | - |
Onechain Immunotherapeutics
Onechain Immunotherapeutics Medical SpecialtiesHealth Technology Onechain Immunotherapeutics develops oncological therapeutic tools. The company is based in Barcelona, Spain. The Spanish company was founded in 2020 by Pablo Menéndez. The CEO is Jorge Alemany. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jorge Alemany | M | - |
Onechain Immunotherapeutics
Onechain Immunotherapeutics Medical SpecialtiesHealth Technology Onechain Immunotherapeutics develops oncological therapeutic tools. The company is based in Barcelona, Spain. The Spanish company was founded in 2020 by Pablo Menéndez. The CEO is Jorge Alemany. | - |
| Michel Janicot | M | - |
Isarna Therapeutics GmbH
 Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | - |
| Eugen Leo | M | - |
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | 6 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Spanien | 5 | 71,43% |
| Deutschland | 2 | 28,57% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Stefanos Theoharis
- Persönliches Netzwerk
